Therapies using hemoproteins

Details Therapies using hemoproteins Therapies using hemoproteins

2006-09-26

2006-09-26

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S006900, C514S016700, C514S343000, C530S362000, C530S363000, C530S385000

Reexamination Certificate

active

07112563

ABSTRACT:
Herein it is shown that hemoproteins (e.g.,Ascarishemoglobin, myoglobin, flavohemoglobins) have NO-consuming and deoxygenase activities. The invention provides a method of reducing the concentration of oxygen and/or nitric oxide in a mammal. The method of the invention comprises administering a therapeutically effective amount of a hemoprotein having NO-activated deoxygenase activity or an enzymatically active fragment thereof to a mammal. The method can be used to treat a mammal having pathologically proliferating cells, such as a tumor. In one embodiment, the hemoprotein is administered to reduce the oxygen concentration of a tumor. In another embodiment, the hemoprotein is administered together with a cytotoxic agent to treat a mammal having a tumor. The invention also provides a method of enzymatically generating toxic reactive oxygen species in a mammal for therapeutic purposes. The method comprises administering a therapeutically effective amount of a hemoprotein to a mammal. The invention also provides a composition comprising a hemoprotein having deoxygenase activity or an enzymatically active fragment thereof and a physiologically acceptable carrier. In one embodiment, the composition further comprises a cytotoxic agent and/or a reducing agent. The invention further provides a method of treating a mammal infected withAscarissp., comprising administering to said mammal a therapeutically effective amount of an inhibitor of NO synthase. The NO-consuming activity of a hemoprotein (e.g., a flavohemoglobin) can be used in a treatment where constriction of blood vessels is desirable, or where it is otherwise desirable to reduce NO concentration, as in inflammation.

REFERENCES:
patent: 5449688 (1995-09-01), Wahl et al.
patent: 6297281 (2001-10-01), Chabrier de Lassauniere et al.
patent: WO 98/08653 (1998-03-01), None
Gura T., Science 1997 vol. 278, pp. 1041-1042.
Poole et al., Proc. R. Soc. Lond. B (1994) vol. 255, pp. 251-258.
Minning, D. et al. “Ascarishaemoglobin is a nitric oxide activated ‘deoxygenase’,”Nature401:497-502 (1999).
Chinje, E. and Stratford, I. “Role of nitric oxide in growth of solid tumors: a balancing act,”Essays Biochem.,32:61-72 (1997).
Crawford, M. and Goldberg, D. “Role for theSalmonellaFlavohemoglobin in Protection from Nitric Oxide,”J. Biol. Chem.,273:12543-12547 (1998).
Gardner, P. et al., “Nitric oxide dioxygenase: An enzymic function for flavohemoglobin,”Proc. Natl. Acad. Sci. USA,95:10378-10383 (1998).
Hausladen, A. et al., “Nitrosative stress: Metabolic pathway involving flavohemoglobin,”Proc. Natl. Acad. Sci. USA,95:14100-14105 (1998).
Kloek, A. et al., “The Tyrosine B10 Hydroxyl Is Crucial for Oxygen Avidity ofAscarisHemoglobin,”Journ. Biol. Chem.,269:2377-2379 (1994).
Membrillo-Hernández, J. et al., “The flavohaemoglobin (HMP) ofEscherichia coligenerates superoxide in vitro and causes oxidative stress in vivo,”FEBS,32:141-144 (1996).
Poole, Robert. “Oxygen reactions with bacterial oxidases and globins: binding, reduction and regulation,”Antonie Leeuwenhuek,65:289-310 (1994).
Poole, Robert, et al., “Reactions of theEscherichia coliflavohaemoglobin (Hmp) with oxygen and reduced nicotinamide adenine dinucleotide: evidence for oxygen switching of flavin oxidoreduction and a mechanism for oxygen sensing”,Proc. R. Soc. Lond.,255:251-258 (1994).
Thomsen, L.L., et al., “Role of nitric oxide in tumour progression: Lessons from human tumours”,Cancer and Metastasis Reviews,17:107-118 (1998).
Tozer, G.M., et al., “Nitric Oxide in Tumour Biology and Cancer Therapy. Part 2: Therapeutic Implications”,Clinical Oncology,9:357-364 (1997).
Wennmalm, A., et al., “Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin”,Br. J. Pharmacol.,106:507-508 (1992).

Affiliated with

Also associated with

Rating

Therapies using hemoproteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapies using hemoproteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapies using hemoproteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3562148